<DOC>
	<DOCNO>NCT01235026</DOCNO>
	<brief_summary>The purpose study determine whether daily administration synbiotic ( oligofructose Bifidobacterium animalis subsp . lactis Bb12 ) six week contribute improve glucose tolerance low grade inflammation ( reflect plasmatic concentration ultrasensitive CRP , IL-6 , sCD14 LPS-binding protein ) obese subject .</brief_summary>
	<brief_title>Synbiotics Low Grade Inflammation Obese Subjects</brief_title>
	<detailed_description>Obesity associate spectrum metabolic disorder include high blood pressure , dyslipidemia , insulin resistance state low grade inflammation predispose individual development type-2 diabetes mellitus cardiovascular disease . The intestinal microbiota recently propose new actor development obesity complication . In animal model , high-fat diet show affect intestinal microbiota , increase colonic gram-negative bacteria lipopolysaccharide ( LPS ) concentration , result impaired gastrointestinal barrier function subsequent endotoxinemia animal . This phenomenon would trigger chronic inflammatory metabolic disorder lead insulin resistance complication hepatic steatosis . Probiotics prebiotics GRAS ( Generally recognize safe ) food ingredient propose maintain balance intestinal microbiota . Studies mice feed high fat diet show administration oligofructose increase count Bifidobacterium spp . colon correlatively induced decrease endotoxinemia low-grade inflammation time improve insulin sensitivity . On basis antecedent , aim study determine whether intake synbiotic product ( B. animalis subsp . lactis BB12+ Oligofructose ) six week contribute improve low grade inflammation glucose tolerance obese subject . Obese subject randomize two group ( Synbiotic Placebo ) stratify sex age . Anthropometric data ( body composition Bod-pod , weight , height , waist circumference ) systolic diastolic blood pressure register . A food survey carry trained dietitian quantify fat consumption . Each subject Synbiotic group must ingest one gram BB12 ( contain 1010 CFU ) 5 g oligofructose twice day 6 week Control group receive correspond placebo ( maltodextrin ) . Digestive symptom well stool frequency consistency register daily study use ad hoc form Bristol Chart . Blood sample obtain baseline , end six week period one month end treatment , determine lipid profile ultrasensitive C-reactive protein ( CRP ) ; plasmatic biomarkers inflammation include IL-6 , LPS bind protein sCD14 also determine Elisa use commercial kit . At time , glycemia /insulinemia curve perform fasted subject , well intestinal permeability test ( lactulose/mannitol/sucralose ) ass gut barrier function . A fresh stool sample also obtain characterize bacterial population IM ( Bifidobacterium , Lactobacillus , F. prausnitzii , Bacteroides Clostridium cluster ) real-time PCR .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>BMI &gt; 30 Nonsmokers Current digestive disease antecedents chronic digestive disease and/or malabsorption ( celiac disease , Inflammatory bowel disease , gastroduodenal ulcer , digestive malignancy , etc ) Use drug could interfere intestinal microbiota integrity gut barrier function ( antibiotic , antiinflammatory drug , laxative , prokinetics , etc . ) three week precede start study Treatments ( medication nutritional program ) affect body weight glucose control Basal glycemia &gt; 130mg/dl ( evaluate glucosemeter ) Immunodeficiencies ( HIV , chemotherapy , radiotherapy , organ transplant ) . Current participation recent previous participation another clinical trial . Pregnant breastfeed woman . Consumption probiotic product Drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Type-2 Diabetes</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Low grade inflammation</keyword>
	<keyword>Metabolic endotoxinemia</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Lipopolysaccharide</keyword>
	<keyword>LPS-binding protein</keyword>
	<keyword>sCD14</keyword>
	<keyword>Synbiotic</keyword>
	<keyword>Oligofructose</keyword>
	<keyword>Bifidobacterium animalis subsp . lactis Bb12</keyword>
	<keyword>probiotic</keyword>
	<keyword>Prebiotic</keyword>
</DOC>